Aplagon

Aplagon is a clinical-stage biotechnology company developing APAC, an antiplatelet and anticoagulant therapy for treating thrombo-inflammatory diseases. From its funding announcement.

€5M UndisclosedRaised 4 months agoHelsinki, FinlandBiotech & PharmaFinland
Visit website →

In their own words

What Aplagon says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "clinical-stage biotechnology company developing APAC, an antiplatelet and anticoagulant therapy for treating thrombo-inflammatory diseases". Source

Market expansionResearch and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where Aplagon is today

Aplagon announced a funding round of €5M on 17 June 2026, led by Fåhraeus Startup and Growth AB (FSG) and the European Innovation Council (EIC) Fund.

Latest round
Undisclosed
Amount
€5M
Announced
17 June 2026
Headquarters
Helsinki, Finland
Sector
Biotech & Pharma
Growth stage
Growth
Investors
Also participating
Finnish investors, Jenny & Antti Wihuri Foundation, Innovestor, Gösta Serlachius Fine Arts Foundation
Relevant leadership
CEO Aki Prihti

Momentum AfterRaise intelligence

AfterRaise Score

36
Established
0 funding signals in the last 90 days
Funding recency
18/40
announced within the last 6 months
Round scale
8/25
round size relative to the market
Funding stage
10/20
Undisclosed
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 17 June 2026
    €5M raised
    Led by Fåhraeus Startup and Growth AB (FSG) and the European Innovation Council (EIC) Fund.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • New market entry
  • First local hires in the new market
  • Local entity and legal setup
  • Research programme expansion

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Licensing and BD partnerships
  • Market-entry advisers
  • Local employment infrastructure

Based on the Biotech & Pharma sector, a Growth round and the priorities the company itself set out. Not a statement of fact.

Medium momentum3 connected signals
  • 17 June 2026€5M round announced
  • 17 June 2026Stated priority: market expansion
  • 17 June 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Aplagon is open to

Not yet specified

Aplagon has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Aplagon

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Aplagon?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector